<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699049</url>
  </required_header>
  <id_info>
    <org_study_id>SMK-1</org_study_id>
    <nct_id>NCT00699049</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of Any Alpha Blocker Monotherapy and Any Alpha Blocker Plus Solifenacin in Men With Residual Overactive Bladder Symptoms of Urinary Frequency and Urgency With/Without Urgency Incontinence After Previous Monotherapy With Any Alpha Blocker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KYU-SUNG LEE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore additional benefit of solifenacin after 12-week
      treatment, compared with alpha blocker monotherapy in men with residual OAB symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement level of patients' individual satisfaction</measure>
    <time_frame>At weeks 4 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in urgency episodes</measure>
    <time_frame>At weeks 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OAB symptom scores</measure>
    <time_frame>At weeks 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QoL score by OAB-q</measure>
    <time_frame>At weeks 4 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Alpha blocker and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha blocker and solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha blocker</intervention_name>
    <description>oral</description>
    <arm_group_label>Alpha blocker and placebo</arm_group_label>
    <arm_group_label>Alpha blocker and solifenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Alpha blocker and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>Alpha blocker and solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent symptoms of OAB as verified by the 3 day voiding diary, defined by:

               -  symptoms of urinary urgency (defined as a level of &gt;=3 in a 5 point urgency
                  scale) at least two episode per 24 hours and

               -  symptoms of urinary frequency ( &gt;8 micturitions per 24 hours)

          -  On a stable dose of tamsulosin for at least 1 month

        Exclusion Criteria:

          -  Previous history of acute urinary retention

          -  Patients have a baseline post-void residual (PVR) which exceeded 50% of voided urine
             volume

          -  Any condition that is a contraindication for anticholinergic treatment, including
             uncontrolled narrow-angled glaucoma, urinary retention or gastric retention

          -  Symptomatic acute urinary tract infection (UTI) during the screening period

          -  Treatment within the 14 days preceding randomization, or expected to initiate
             treatment during the study with any anticholinergic drugs and drug treatment for
             overactive bladder

          -  A 5-alpha reductase inhibitor if started less than 3 months prior to screening

          -  Patients with previous urethral, prostate or bladder neck surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Alpha blocker</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urgency incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

